Fulgent Genetics (FLGT) Gross Margin (2015 - 2026)

Fulgent Genetics has disclosed Gross Margin across 12 years of filings, most recently posting 30.21% for Q1 2026.

• Gross Margin for Q1 2026 came in at 30.21%, down 838.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 52.24% (up 1344.0% YoY), and the FY2025 annual result was 40.56%, up 274.0% from the prior year.
• Gross Margin came in at 30.21% for Q1 2026 at Fulgent Genetics, down from 8145.5% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 8145.5% in Q4 2025 to a low of 28.43% in Q1 2023.
• The 5-year median for Gross Margin is 40.19% (2024), against an average of 547.65%.
• Across the five-year window, Gross Margin sank 4730 bps in 2023 and soared 810371 bps in 2025, its largest moves.
• Fulgent Genetics' Gross Margin stood at 43.63% in 2022, then dropped by 18 bps to 35.78% in 2023, then rose by 17 bps to 41.79% in 2024, then soared by 19392 bps to 8145.5% in 2025, then slumped by 100 bps to 30.21% in 2026.
• The last three Gross Margin figures came in at 30.21% (Q1 2026), 8145.5% (Q4 2025), and 42.24% (Q3 2025), per Business Quant data.